T he American Heart Association (AHA) has had a longstanding commitment to provide information about the role of nutrition in cardiovascular disease (CVD) risk reduction. Many activities have been and are currently directed toward this objective, including issuing AHA Dietary Guidelines periodically (most recently in 2000 1 ) and Science Advisories and Statements on an ongoing basis to review emerging nutrition-related issues. The objective of the AHA Dietary Guidelines is to promote healthful dietary patterns. A consistent focus since the inception of the AHA Dietary Guidelines has been to reduce saturated fat (and trans fat) and cholesterol intake, as well as to increase dietary fiber consumption. Collectively, all the AHA Dietary Guidelines have supported a dietary pattern that promotes the consumption of diets rich in fruits, vegetables, whole grains, low-fat or nonfat dairy products, fish, legumes, poultry, and lean meats. This dietary pattern has a low energy density to promote weight control and a high nutrient density to meet all nutrient needs.
As reviewed in the first AHA Science Advisory 2 on antioxidant vitamins, epidemiological and population studies reported that some micronutrients may beneficially affect CVD risk (ie, antioxidant vitamins such as vitamin E, vitamin C, and ␤-carotene). Recent epidemiological evidence 3 is consistent with the earlier epidemiological and population studies (reviewed in the first Science Advisory). 2 These findings have been supported by in vitro studies that have established a role of oxidative processes in the development of the atherosclerotic plaque. Underlying the atherosclerotic process are proatherogenic and prothrombotic oxidative events in the artery wall that may be inhibited by antioxidants. The 1999 AHA Science Advisory 2 recommended that the general population consume a balanced diet with emphasis on antioxidant-rich fruits, vegetables, and whole grains, advice that was consistent with the AHA Dietary Guidelines at the time. In the absence of data from randomized, controlled clinical trials, no recommendations were made with regard to the use of antioxidant supplements.
In the past 5 years, a number of controlled clinical studies have reported the effects of antioxidant vitamin and mineral supplements on CVD risk (see Tables 1 through 3 ). 4 -21 These studies have been the subject of several recent reviews [22] [23] [24] [25] [26] and formed the database for the present article. In general, the studies presented in the tables differ with regard to subject populations studied, type and dose of antioxidant/cocktail administered, length of study, and study end points. Overall, the studies have been conducted on post-myocardial infarction subjects or subjects at high risk for CVD, although some studied healthy subjects. In addition to dosage differences in vitamin E studies, some trials used the synthetic form, whereas others used the natural form of the vitamin. With regard to the other antioxidants, different doses were administered (eg, for ␤-carotene and vitamin C). The antioxidant cocktail formulations used also varied. Moreover, subjects were followed up for at least 1 year and for as long as 12 years. In addition, a meta-analysis of 15 studies (7 studies of vitamin E, 50 to 800 IU; 8 studies of ␤-carotene, 15 to 50 mg) with 1000 or more subjects per trial has been conducted to ascertain the effects of antioxidant vitamins on cardiovascular morbidity and mortality. 27 Collectively, for the most part, clinical trials have failed to demonstrate a beneficial effect of antioxidant supplements on CVD morbidity and mortality. With regard to the meta-analysis, the lack of efficacy was demonstrated consistently for different doses of various antioxidants in diverse population groups.
Although the preponderance of clinical trial evidence has not shown beneficial effects of antioxidant supplements, evidence from some smaller studies documents a benefit of ␣-tocopherol (Cambridge Heart AntiOxidant Study, 13 Secondary Prevention with Antioxidants of Cardiovascular disease in End-stage renal disease study), 15 ␣-tocopherol and slow-release vitamin C (Antioxidant Supplementation in Atherosclerosis Prevention study), 16 and vitamin C plus vitamin E (Intravascular Ultrasonography Study) 17 on cardio-vascular end points. To complicate matters, there is some evidence of potentially adverse effects of antioxidant supplements on CVD as assessed by angiographic end points. In the Women's Angiographic Vitamin and Estrogen Study, 21 postmenopausal women with coronary disease on hormone replacement therapy given vitamin E plus vitamin C had an unexpected significantly higher all-cause mortality rate and a trend for an increased cardiovascular mortality rate compared with the vitamin placebo women. Likewise, in the HDL-Atherosclerosis Treatment Study, 20 subjects with angiographically demonstrated coronary artery disease on simvastatin/ niacin and an antioxidant cocktail (vitamin E, ␤-carotene, vitamin C, and selenium) had a 0.7% progression in stenosis after 3 years, compared with 0.4% regression in the group on only simvastatin/niacin. Thus, antioxidant supplements may have interfered with the efficacy of statin-plus-niacin therapy. Further evaluation showed that the addition of the antioxidant vitamins blunted the expected rise in the protective HDL-2 cholesterol and apolipoprotein A1 subfractions of HDL. In general, the studies showing either positive or adverse effects (especially for vitamins E, vitamins E and C, and the antioxidant cocktails) are much smaller studies than the larger clinical trials that consistently have not shown any beneficial effects of antioxidant supplements on several CVD end points.
Thus, in agreement with many in the field, we conclude that the existing scientific database does not justify routine use of antioxidant supplements for the prevention and treatment of CVD. [25] [26] [27] [28] 29 This conclusion is consistent with the American College of Cardiology/American Heart Associa- tion 2002 Guideline Update for the management of patients with chronic stable angina, which states that there is no basis for recommending that patients take vitamin C or E supplements or other antioxidants for the express purpose of preventing or treating coronary artery disease (Class III, Level A Evidence). 30 In addition, "Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women" 31 concludes that antioxidant vitamin supplements should not be used to prevent CVD, pending the results of ongoing trials (Class III, Level A Evidence). Whether or not to use vitamin E in highly specialized situations, such as in subjects on hemodialysis, 15 also remains unsettled until further studies in this setting are conducted. Moreover, although there is some evidence of beneficial effects of antioxidant supplements, it also is apparent that some studies suggest adverse effects of antioxidant supplement use. An important question is: What should we be doing in clinical practice? At this time, there is little reason to advise that individuals take antioxidant supplements to reduce risk of CVD. Nonetheless, we recommend that antioxidant research continue in order to resolve whether the oxidative modification hypothesis is relevant to human atherosclerosis. It will be important to clarify the discrepancy between the randomized clinical trials and the population studies. The positive findings from observational studies with regard to vitamin E supplementation and lower rates of CVD may be a reflection of the generally healthy lifestyles and dietary intakes of supplement users. At this time, the scientific evidence supports recommending consumption of a diet high in food sources of antioxidants and other cardioprotective nutrients, such as fruits, vegetables, whole grains, and nuts, instead of antioxidant supplements to reduce risk of CVD. 32, 33 It does not support the use of antioxidant vitamin supplements.
The failure of these particular trials does not necessarily rule out a role for oxidative mechanisms in the pathogenesis of human atherosclerosis. Antioxidant compounds cannot be indiscriminately lumped together; they differ quantitatively and even qualitatively from one another. We still know too little about the oxidative mechanisms in vivo and lack biochemical markers with which to evaluate candidate antioxidant compounds. Moreover, antioxidant treatment may need to begin earlier in life to be effective. The discrepancy between the impressive observational data and the clinical trials could reflect the difference between lifelong exposure to an antioxidant-rich diet and a limited, 5-year exposure to antioxidant supplements. However, several other factors (such as identity, type, and form of antioxidant; particular antioxidant combinations; trial design issues; outcome measures; length; populations under study; etc) could also be important in explaining the lack of agreement between the predicted positive benefits and the results of the clinical trials conducted to date. Clearly, further research is needed.
Summary
At this time, the scientific data do not justify the use of antioxidant vitamin supplements for CVD risk reduction. This position is consistent with recommendations that have been made by the AHA in 2004 31 for the prevention of CVD in women as well as by the American College of Cardiology and AHA in 2002 30 for patients with chronic stable angina. CVD risk reduction can be achieved by the long-term consumption of diets consistent with the AHA Dietary Guidelines; 1 the long-term maintenance of a healthy body weight through balancing energy intake with regular physical activity; and the attainment of desirable blood cholesterol and lipoprotein profiles and blood pressure levels. No consistent data suggest that consuming micronutrients at levels exceeding those provided by a dietary pattern consistent with AHA Dietary Guidelines will confer additional benefit with regard to CVD risk reduction. 
